Cipla Ltd, India's fifth-largest drugmaker by sales, on Wednesday reported a 35 percent fall in quarterly profit, missing analysts' estimates, mainly due to lower sales in the emerging markets and Europe.
Net profit in the July-September quarter was 3.54 billion rupees ($53.3 million), down from 5.43 billion rupees during the same period a year earlier. That compared with the average estimate of 3.92 billion rupees from analysts in a Thomson Reuters I/B/E/S poll.
Sales in India, Cipla's biggest market, rose 21 percent in the quarter, the company said in a statement.
North America, where Cipla has been working on building up its presence, contributed 18 percent to sales in the second-quarter. Sales from the region rose 38 percent.
Those rises could not offset a 27 percent fall in Europe sales, and a 1 percent fall in emerging markets, which are Cipla's second-largest contributor to sales.
(Reuters)
_20240620145931_original_image_29.webp)
_20241029090926_original_image_15.webp)
_20241022152318_original_image_45.webp)
